Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.52 |
| ▸ | HTR1D | P28221 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740922 | 0.78 | HTR1B (0.46) | HTR1BCHRNB2CHRNA4 | |
| SCHEMBL19825529 | 0.77 | CHRNB2 (0.43) | HTR1BHTR1DCHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL24042179 | 0.77 | CHRNB2 (0.43) | HTR1BHTR1DCHRNB2CHRNA4TAAR1 | |
| SCHEMBL2569101 | 0.75 | HTR1B (0.55) | HTR1BHTR1DCHRNB2CHRNA4HRH3 | |
| SCHEMBL12501346 | 0.75 | HRH3 (0.44) | HTR1BHTR1DCHRNB2CHRNA4HRH3 | |
| SCHEMBL22536868 | 0.74 | HTR1B (0.52) | HTR1BHTR1DCHRNB2CHRNA4HRH3 | |
| SCHEMBL7005477 | 0.74 | ALDH1A1 (0.33) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL14562245 | 0.74 | MTNR1A (0.59) | ALDH1A1LMNAALOX15KDM4E | |
| SCHEMBL4280446 | 0.73 | NPC1 (0.46) | ALDH1A1KDM4E | |
| SCHEMBL27137198 | 0.72 | HTR1B (0.57) | HTR1BHTR1DCHRNB2CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20070185116-A1 | Bicyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185116-A1 | Bicyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185116-A1 | Bicyclic compounds | KCNN3, KCNJ1, KCNJ2 | HTR1B 983/4885HTR1D 720/4885CHRNB2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.